{
    "title": "Individual feed for https://medicalxpress.com/rss-feed/",
    "link": "https://medicalxpress.com/rss-feed/",
    "description": "Individual feed output.",
    "lastBuildDate": "2025-12-08T07:22:05.466636",
    "items": [
        {
            "title": "Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy",
            "link": "https://medicalxpress.com/news/2025-12-azaven-combination-outperforms-standard-aml.html",
            "description": "In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venet...",
            "pubDate": "2025-12-08T11:37:23",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture7.png"
        },
        {
            "title": "New findings support a chemo-free approach for treating Ph+ ALL",
            "link": "https://medicalxpress.com/news/2025-12-chemo-free-approach-ph.html",
            "description": "A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic ...",
            "pubDate": "2025-12-08T11:36:34",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png"
        },
        {
            "title": "Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes",
            "link": "https://medicalxpress.com/news/2025-12-adding-epcoritamab-standard-line-therapy.html",
            "description": "In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or ...",
            "pubDate": "2025-12-08T11:35:22",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture2.png"
        },
        {
            "title": "Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL",
            "link": "https://medicalxpress.com/news/2025-12-covalent-btki-pirtobrutinib-frontline-therapy.html",
            "description": "Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate i...",
            "pubDate": "2025-12-08T11:34:35",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture8.png"
        },
        {
            "title": "Roughly one-third of families with children being treated for leukemia struggle to pay living expenses",
            "link": "https://medicalxpress.com/news/2025-12-roughly-families-children-leukemia-struggle.html",
            "description": "Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL)—the most common pediatric cancer—develop seriou...",
            "pubDate": "2025-12-08T11:33:37",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png"
        }
    ]
}